Search Result

Results for "

Lysine-specific demethylase 1 (LSD1)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Histone Demethylase (37) Apoptosis (11) Dopamine Receptor (2) HDAC (3) Monoamine Oxidase (4) TNF Receptor (1)
By Research Areas:	Cancer (35) Cardiovascular Disease (3) Inflammation/Immunology (1) Neurological Disease (5)

Inhibitors & Agonists

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Histone Demethylase PSMA SNIPERs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160191

LSD1-IN-30

Histone Demethylase Cancer

LSD1-IN-30 (compound 3) is a potent inhibitor of lysine-specific demethylase 1 (LSD1), with the IC₅₀ value of 0.291 μM .

LSD1-IN-30	Histone Demethylase	Cancer
LSD1-IN-30 (compound 3) is a potent inhibitor of lysine-specific demethylase 1 (LSD1), with the IC₅₀ value of 0.291 μM .

HY-147697

LSD1-IN-21	Histone Demethylase TNF Receptor	Inflammation/Immunology Cancer
LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated *LSD1* (Lysine specific demethylase-1) inhibitor, with an IC₅₀ of 0.956 µM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity .

HY-151191

LSD1-IN-22	Histone Demethylase	Cancer
LSD1-IN-22 is a potent Lysine-specific demethylase 1 (LSD1) inhibitor with a K_i value of 98 nM. LSD1-IN-22 has anti-proliferative activity against certain cancer cells .

HY-151194

LSD1/2-IN-4	Histone Demethylase	Cancer
LSD1/2-IN-4, a PCPA derivative, is an inhibitor of **lysine-specific demethylase 1 (LSD1) and lysine-specific demethylase 2 (LSD2)*. LSD1/2-IN-4 inhibits LSD1* and LSD2 with K_i values of 0.11 μM and 130 μM, respectively. LSD1/2-IN-4 can be used for the research of several cancers including T-cell acute lymphoblastic leukemia (TALL) .

HY-100859

LSD1-IN-5
LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 .

HY-100860

LSD1-IN-6	Histone Demethylase	Cancer
LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 .

HY-19612B

DDP-38003 trihydrochloride	Histone Demethylase	Cancer
DDP-38003 trihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM.

HY-110277

S2101

Histone Demethylase Cancer

S2101 is a lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 0.99 μM, K_i of 0.61 μM and K_inact/K_i of 4560 M/s .

S2101	Histone Demethylase	Cancer
S2101 is a **lysine-specific demethylase 1** (LSD1) inhibitor with an IC₅₀ of 0.99 μM, K_i of 0.61 μM and K_inact/K_i of 4560 M/s .

HY-12645

NCL1	Histone Demethylase	Cancer
NCL1 is a phenylcyclopropylamine (PCPA)-based **Lysine-specific demethylase 1 (LSD1)** inhibitor. NCL1 selectively inhibits LSD1 in preference to LSD2, with IC₅₀ values of 2.5 and 26 μM for LSD1 and LSD2, respectively .

HY-19612A

DDP-38003 dihydrochloride

DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM .

DDP-38003 dihydrochloride
DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM .

HY-141677

INCB059872	Histone Demethylase	Cancer
INCB059872 is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 can be used for the research of myeloid leukemia .

HY-141677A

INCB059872 dihydrochloride	Histone Demethylase	Cancer
INCB059872 dihydrochloride is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 dihydrochloride can be used for the research of myeloid leukemia .

HY-151192

LSD1/2-IN-3	Histone Demethylase	Cancer
LSD1/2-IN-3 is a selective inhibitor of **lysine-specific demethylase 1** (LSD1), with a K_i value of 11 nM instead of 7 μM for *LSD2. There is aberrant expression of LSD1* in cancer stem cells, LSD1/2-IN-1 inhibits *LSD1* cell proliferation .

HY-160183

LSD1-IN-29

Histone Demethylase Cancer

LSD1-IN-29 (compound 6) is a Lysine specific demethylase 1 (LSD1) inhibitor with the IC₅₀ of 19 nM .

LSD1-IN-29	Histone Demethylase	Cancer
LSD1-IN-29 (compound 6) is a Lysine specific demethylase 1 (LSD1) inhibitor with the IC₅₀ of 19 nM .

HY-115747

Namoline	Histone Demethylase	Cancer
Namoline, a γ-pyrone, is a selective and reversible **Lysine-specific demethylase 1 (LSD1)** inhibitor with an IC50 of 51 μM in a HRP-coupled enzymatic assay. Namoline impairs LSD1 demethylase activity and blocks cell proliferation. Namoline has the potential for androgen-dependent prostate cancer research .

HY-100546A

GSK-LSD1 dihydrochloride 5 Publications Verification	Histone Demethylase Monoamine Oxidase	Cancer
GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 16 nM.

HY-129388A

Pulrodemstat CC-90011; LSD1-IN-7	Histone Demethylase	Cancer
Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of **lysine specific demethylase-1 (LSD1) with an IC₅₀** of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-129388B

Pulrodemstat benzenesulfonate 2 Publications Verification CC-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate	Histone Demethylase	Cancer
CC-90011 benzenesulfonate is a potent, selective, reversible and orally active inhibitor of **lysine specific demethylase-1 (LSD1) with an IC₅₀** of 0.25 nM. CC-90011 benzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-110130

RN-1 dihydrochloride	Histone Demethylase	Cardiovascular Disease Cancer
RN-1 dihydrochloride is a potent, brain-penetrant, irreversible and selective **lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀** of 70 nM. RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC₅₀ values of 0.51 μM and 2.785 μM respectively .

HY-12635

SP2509

5+ Cited Publications

Histone Demethylase Apoptosis Cancer

SP2509 is a potent and selective antagonist of lysine specific demethylase 1 (LSD1) with an IC₅₀ of 13 nM .

SP2509 5+ Cited Publications	Histone Demethylase Apoptosis	Cancer
SP2509 is a potent and selective antagonist of **lysine specific demethylase 1 (LSD1) with an IC₅₀** of 13 nM .

HY-122635A

T-448	Histone Demethylase	Neurological Disease
T-448 is a specific, orally active and irreversible inhibitor of **lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC₅₀** of 22 nM. T-448 enhances H3K4 methylation in primary cultured rat neurons .

HY-129388

Pulrodemstat Methylbenzenesulfonate CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate	Histone Demethylase	Cancer
CC-90011 Methylbenzenesulfonate is a potent, selective, reversible and orally active inhibitor of **lysine specific demethylase-1 (LSD1) with an IC₅₀** of 0.25 nM. CC-90011 Methylbenzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 Methylbenzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-17447A

Tranylcypromine hydrochloride 4 Publications Verification SKF 385 hydrochloride
Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 *(LSD1/BHC110)* and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC₅₀s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression .

HY-117226A

GSK 690 Hydrochloride 1 Publications Verification	Histone Demethylase	Others
GSK 690 (Hydrochloride) is a reversible inhibitor of lysine specific demethylase 1 *(LSD1), with a K_d* value of 9 nM and a biochemical IC₅₀ of 37 nM.

HY-117226

GSK 690

Histone Demethylase Cancer

GSK 690 is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a K_d value of 9 nM and a biochemical IC₅₀ of 37 nM.

GSK 690	Histone Demethylase	Cancer
GSK 690 is a reversible inhibitor of lysine specific demethylase 1 *(LSD1), with a K_d* value of 9 nM and a biochemical IC₅₀ of 37 nM.

HY-122635

T-448 free base	Histone Demethylase	Neurological Disease
T-448 free base is a specific, orally active and irreversible inhibitor of **lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC₅₀** of 22 nM. T-448 free base enhances H3K4 methylation in primary cultured rat neurons .

HY-152032

LSD1-IN-23	Histone Demethylase	Cancer
LSD1-IN-23 is a competitive/non-competitive mixed inhibitor of **lysine specific demethylase 1 (LSD1)*. LSD1-IN-23 has LSD1* inhibitory activity with an IC₅₀ value of 0.58 μM. LSD1-IN-23 can be used for the research of neuroblastoma (NB) .

HY-18632A

GSK2879552 dihydrochloride Maximum Cited Publications 10 Publications Verification	Histone Demethylase	Cancer
GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of **lysine specific demethylase 1 (LSD1/KDM1A)**, with potential antineoplastic activity .

HY-18632

GSK2879552 Maximum Cited Publications 10 Publications Verification	Histone Demethylase	Cancer
GSK2879552 an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/ KDM1A), with potential antineoplastic activity .

HY-B1496

Tranylcypromine hemisulfate 4 Publications Verification SKF 385 hemisulfate	Monoamine Oxidase Histone Demethylase	Neurological Disease
Tranylcypromine (SKF 385) hemisulfate is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hemisulfate is also a **lysine-specific demethylase 1 (LSD1)** inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Tranylcypromine has antidepressant effects .

HY-110021

Fenoldopam hydrochloride SKF 82526 hydrochloride	Dopamine Receptor Histone Demethylase Apoptosis	Cardiovascular Disease Cancer
Fenoldopam (SKF 82526) hydrochloride is a D₁ receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC₅₀=0.8974 μM). Fenoldopam hydrochloride shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .

HY-B0735A

Fenoldopam mesylate 4 Publications Verification Fenoldopam methanesulfonate; SKF-82526 mesylate	Dopamine Receptor Apoptosis	Cardiovascular Disease Cancer
Fenoldopam mesylate (SKF-82526) is a D₁ receptor agonist and a novel **lysine-specific demethylase 1** (LSD1) inhibitor (IC₅₀=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .

HY-17447SA

Tranylcypromine-d5 hydrochloride SKF 385-d₅ hydrochloride	Monoamine Oxidase Histone Demethylase	Neurological Disease
Tranylcypromine-d₅ (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis[1][2].

HY-131970

LSD1/HDAC6-IN-1	Histone Demethylase HDAC	Cancer
LSD1/HDAC6-IN-1 is an orally active dual inhibitor of lysine specific demethylase 1(LSD1)/Histone deacetylase 6 (HDAC6), with anti-tumor activity. LSD1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM) .

HY-109169

Bomedemstat IMG-7289	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) is an orally active and irreversible **lysine-specific demethylase 1** (LSD1) inhibitor. Bomedemstat can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-109169B

Bomedemstat hydrochloride IMG-7289 hydrochloride	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) hydrochloride is an orally active and irreversible **lysine-specific demethylase 1** (LSD1) inhibitor. Bomedemstat hydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat hydrochloride shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-109169C

Bomedemstat dihydrochloride IMG-7289 dihydrochloride	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) dihydrochloride is an orally active and irreversible **lysine-specific demethylase 1** (LSD1) inhibitor. Bomedemstat dihydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat dihydrochloride shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride (1S,2R)-SKF 385-d₅ hydrochloride	Monoamine Oxidase	Neurological Disease
(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

HY-109169A

Bomedemstat ditosylate IMG-7289 ditosylate	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) ditosylate is an orally active and irreversible **lysine-specific demethylase 1** (LSD1) inhibitor. Bomedemstat ditosylate can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat ditosylate shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

HY-151190

cis-4-Br-2,5-F2-PCPA S1024	Histone Demethylase	Cancer
cis-4-Br-2,5-F2-PCPA (S1024) is a selective inhibitor of **lysine-specific demethylase 1** (LSD1), with a K_i value of 94 nM instead of 8.4 μM for *LSD2. There is aberrant expression of LSD1* in cancer stem cells, cis-4-Br-2,5-F2-PCPA inhibits *LSD1* cell proliferation and by increasing the level of dimethylated histone H3 at K4 (H3K4) in CCRF-CEM cells .

HY-16012

Domatinostat tosylate 3 Publications Verification 4SC-202	HDAC Apoptosis	Cancer
Domatinostat tosylate (4SC-202) is a selective class I HDAC inhibitor with IC₅₀ of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against **Lysine specific demethylase 1 (LSD1)**.

HY-16012A

Domatinostat 3 Publications Verification 4SC-202 free base	HDAC Apoptosis	Cancer
Domatinostat (4SC-202 free base) is a selective class I HDAC inhibitor with IC₅₀ of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against **Lysine specific demethylase 1 (LSD1)**.

HY-136522

S2116	Histone Demethylase Apoptosis	Cancer
S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent **lysine-specific demethylase 1 (LSD1) inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2116 induces apoptosis** in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2116 significantly retardes the growth of T-ALL cells in xenotransplanted mice .

HY-136523

S2157	Histone Demethylase Apoptosis	Cancer
S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent **lysine-specific demethylase 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis** in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells .

	LSD1 Protein, Human (sf9, His-GST) Lysine-specific histone demethylase 1A; KDM1A; AOF2; KDM1; KIAA0601; LSD1	Human	Sf9 insect cells
	The LSD1 protein is a histone demethylase that modifies histone H3 by demethylating “Lys-4” (H3K4me) and “Lys-9” (H3K9me). It acts as a coactivator or corepressor, oxidizing substrates via FAD to generate imines that are subsequently hydrolyzed. LSD1 Protein, Human (sf9, His-GST) is the recombinant human-derived LSD1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of LSD1 Protein, Human (sf9, His-GST) is 681 a.a., with molecular weight of ~93 kDa.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote